Login to Your Account

Astrazeneca Allies with Taiwan in Drug Repurposing Project

By Dave Silver
Staff Writer

Wednesday, October 23, 2013

TAIPEI, Taiwan – Astrazeneca plc and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) are collaborating to repurpose a basket of clinical-stage drug candidates provided by the London-based big pharma for possible new therapies targeting Asian-prevalent diseases, using an open innovation model of development.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription